SirolimusSafetyImmunosuppressive AgentsTacrolimusSafety ManagementTreatment OutcomeKidney TransplantationCyclosporineMycophenolic AcidPatient SafetyCalcineurinGraft RejectionDrug Therapy, CombinationDrug SubstitutionDouble-Blind MethodTime FactorsLymphangioleiomyomatosisFood SafetyAngiomyolipomaTOR Serine-Threonine KinasesEquipment SafetyDose-Response Relationship, DrugDrug Administration ScheduleGraft SurvivalFollow-Up StudiesProspective StudiesAdministration, OralCoronary RestenosisLymphangiomyomaInjections, IntraocularRetrospective StudiesDrug-Eluting StentsConsumer Product SafetyLiver TransplantationDrug MonitoringTransplantation, HomologousPilot ProjectsKidneyChyleCreatinineCardiovascular AgentsStentsPolyenesDrug CombinationsAntibiotics, AntineoplasticRandomized Controlled Trials as TopicDrug InteractionsDrug ImplantsMedical ErrorsPaclitaxelAntibodies, MonoclonalAntineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsGlomerular Filtration RateClinical Trials as TopicImmunosuppressionTubulin ModulatorsAntibodies, Monoclonal, HumanizedIslets of Langerhans TransplantationTransplantationCoated Materials, BiocompatiblePostoperative ComplicationsFluorescence Polarization ImmunoassayAzathioprineFeasibility StudiesRecurrenceThrombotic MicroangiopathiesOxaloacetic AcidAntineoplastic Combined Chemotherapy ProtocolsPlacebosKaplan-Meier EstimateAdrenal Cortex HormonesDisease Models, AnimalCitrus paradisiDrug Delivery SystemsHeart TransplantationBenzenesulfonatesRenal InsufficiencyPolycystic Kidney, Autosomal DominantAbsorbable ImplantsNeoplasmsBiopsyProduct Surveillance, PostmarketingAcetic AnhydridesKidney Function TestsAntilymphocyte SerumRisk AssessmentArea Under CurveUnrelated DonorsRetreatmentOral UlcerCoronary AngiographyIntention to Treat AnalysisOrganizational CultureTuberous SclerosisDrug SynergismMethotrexateDrug CarriersKetoconazoleSteroids